Company: PRME
Filing Date: 2025-07-02
Form Type: PRE 14A
Source: 0001193125-25-155000
Chunk: 26

Company: Prime Medicine, Inc.
Filing Date: 2025-07-02
Form: PRE 14A
Chunk 26
---
. Cahill, a member of our board of directors, is the managing member of Newpath GP LLC.                                                                                                                |

The address of all entities and Dr. Cahill referenced in this footnote is 800 Boylston Street, Suite 2222, Boston, Massachusetts 02199.

| (7) | Dr. Reine was appointed Chief Executive Officer and director of the Company, effective May 19,                                                                                 
 2025. Consists of: (a) 125,000 shares of common stock held by Dr. Reine and (b) 521,875 shares of common stock underlying options exercisable within 60 days of June 30, 2025. |

| (8) | Consists of: (a) 965,001 shares of common stock held by Dr. Duffield, and (b) 223,240 shares of 
 common stock underlying options exercisable within 60 days of June 30, 2025.                    |

18

| (9) | Dr. Gottesdiener resigned as President, Chief Executive Officer and director of the Company, in each                                                                                                                   
 case effective May 18, 2025. Consists of: (a) 2,310,837 shares of common stock held by Dr. Gottesdiener, (b) 811,127 shares of common stock underlying options exercisable within 60 days of June 30, 2025, (c) 50,241 
 shares of common stock held by Dr. Gottesdiener’s spouse, (d) 682,259 shares of common stock held by the Coolidge GST Trust-2022 (the “Coolidge Trust Shares”), and (e) 1,317,741 shares of common stock held by the   
 Gottesdiener Family GST Trust (the “Gottesdiener Family Trust Shares”). Dr. Gottesdiener disclaims beneficial ownership of the Coolidge Trust Shares and the Gottesdiener Family Trust Shares.                         |

| (10) | Includes 84,062 shares of common stock underlying options exercisable within 60 days of June 30, 2025. |

| (11) | Consists entirely of shares of common stock underlying options exercisable within 60 days of June 30, 
 2025.                                                                                                 |

| (12) | Includes (a) 84,062 shares of common stock underlying options exercisable within 60 days of June 30,       
 2025